AMAG Pharmaceuticals (AMAG) – Bull of the Day
Source: http://www.zacks.com/commentary/11384/AMAG+Pharmaceuticals+%28AMAG%29+-+Bull+of+the+DayPosted on Thursday, July 2nd, 2009 | In Market Commentary, Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -
AMAG Pharmaceuticals Inc. (AMAG) develops superparamagnetic iron oxide nanoparticles for use in pharmaceutical products. The company’s focus is on developing IV iron replacement therapy for anemia in chronic kidney disease and imaging agent to aid in diagnosis.
The company filed the NDA for its lead drug Feraheme in December 2007, and the drug was approved by the FDA on June 30, 2009. Clinical data in over 1,700 patients indicate an excellent safety profile for the drug with lower incidents of heart problems.
Clinical results and eventual approval for additional indications should ensure strong growth in the coming years. We maintain our Buy rating on the shares of AMAG with a target price of $62.Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
Tags for this Post:
AMAG, Fda, Feraheme;, Market Commentary, Stocks to Watch, The Macro Trader, USD, Zacks Market Commentaries
AMAG, Fda, Feraheme;, Market Commentary, Stocks to Watch, The Macro Trader, USD, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.